A5034509828- Diabetes Management and Research
- Diabetes Treatment and Management
- Pancreatic function and diabetes
- Metabolism, Diabetes, and Cancer
- Diabetes and associated disorders
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Diet and metabolism studies
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Pharmacology and Obesity Treatment
- Neurological Disorders and Treatments
- Growth Hormone and Insulin-like Growth Factors
- Natural Antidiabetic Agents Studies
- Protein Kinase Regulation and GTPase Signaling
- Glycosylation and Glycoproteins Research
- Diabetes Management and Education
- Nuclear Structure and Function
- Obesity and Health Practices
- Cancer, Hypoxia, and Metabolism
- Receptor Mechanisms and Signaling
- Diet, Metabolism, and Disease
- Health Systems, Economic Evaluations, Quality of Life
- Lipoproteins and Cardiovascular Health
- Cardiovascular Function and Risk Factors
- Adipose Tissue and Metabolism
- Peroxisome Proliferator-Activated Receptors
Grunberger Diabetes Institute
2016-2025
Wayne State University
2015-2024
Charles University
2016-2024
Oakland University
2014-2024
Cranbrook Academy of Art
2014-2023
American Association of Clinical Endocrinologists
2008-2020
Michigan United
2019
Institute of Endocrinology
2018
Woodward (United States)
2003-2017
Technion – Israel Institute of Technology
2016
While A1C is well established as an important risk marker for diabetes complications, with the increasing use of continuous glucose monitoring (CGM) to help facilitate safe and effective management, it understand how CGM metrics, such mean glucose, correlate. Estimated (eA1C) a measure converting from or self-monitored blood readings, using formula derived readings population individuals, into estimate simultaneously measured laboratory A1C. Many patients clinicians find eA1C be helpful...
To evaluate efficacy and safety of LixiLan (iGlarLixi), a novel titratable fixed-ratio combination insulin glargine (iGlar) lixisenatide (Lixi), compared with both components, iGlar Lixi, given separately in type 2 diabetes inadequately controlled on metformin or without second oral glucose-lowering drug.After 4-week run-in to optimize stop other antidiabetic drugs, participants (N = 1,170, mean duration ∼8.8 years, BMI ∼31.7 kg/m2) were randomly assigned open-label once-daily iGlarLixi...
OBJECTIVE This study assessed the clinical impact of four treatment strategies in adults with type 1 diabetes (T1D): real-time continuous glucose monitoring (rtCGM) multiple daily insulin injections (rtCGM+MDI), rtCGM subcutaneous infusion (rtCGM+CSII), self-monitoring blood MDI (SMBG+MDI), and SMBG CSII (SMBG+CSII). RESEARCH DESIGN AND METHODS 3-year, nonrandomized, prospective, real-world, trial followed 94 participants T1D (rtCGM+MDI, n = 22; rtCGM+CSII, 26; SMBG+MDI, 21; SMBG+CSII, 25)....